BioSpace News Archive

Kineta, Inc. announced today that it will be featured as a presenting company at the H.C. Wainwright 24th Annual Global Investment Conference.

Pretzel Therapeutics, a biotechnology company harnessing the intricacies of mitochondrial biology to develop groundbreaking therapies, launched today with a $72.5 million Series A

AnaptysBio, Inc., a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, announced that the company has sold its royalty interest on future global net sales of Zejula to a wholly-owned subsidiary of DRI Healthcare Trust for up to $45 million.

Triumvira Immunologics announced positive initial clinical data from its ongoing TACTIC‑2 Phase 1/2 trial of TAC01-HER2 in patients with human epidermal growth factor receptor 2 positive solid tumors.

NeoImmuneTech, Inc., a T cell-focused therapeutics company, presented data that suggests that NT-I7 plus pembrolizumab combination treatment enhances infiltration of PD-1+ T cells in cold tumors, at the European Society for Medical Oncology Congress in Paris, France, September 9-13, 2022.

Mirum Pharmaceuticals, Inc. announced that on September 10-11, 2022, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 47,750 shares of common stock and 23,900 restricted stock units to 11 new employees under Mirum’s 2020 Inducement Plan.

Regeneron Pharmaceuticals, Inc. announced positive clinical data for an investigational regimen of PD-1 inhibitor Libtayo® as neoadjuvant monotherapy in stage II to IV resectable cutaneous squamous cell carcinoma.

EpiVax, Inc. is pleased to announce the award of a two-year, $2 million grant from the FDA’s Office of Center for Drug Evaluation and Research to validate a method for immunogenicity risk assessment of host cell proteins for improving biosimilar product development and assessing product interchangeability.

ANI Pharmaceuticals, Inc. announced that Krista L. Davis will join the Company as Chief Human Resources Officer, effective September 12.

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that its collaborator, Bristol Myers Squibb, presented updated Phase 1 results with BMS-986249, a Probody® therapeutic version of ipilimumab, the anti-CTLA-4 antibody, at the ESMO Congress 2022 in Paris, France.